# Aspen Neuroscience Inc. (ASPE)

Source: https://www.quantisnow.com/company/ASPE
Generated: 2026-11-08T06:43:56.714Z

- Ticker: ASPE
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2026
- SEC CIK: 0002124080

## About

Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases with high unmet medical need.

## Latest ASPE news and filings

- 2026-11-06 23:38 UTC [SEC Schedule 13D] [SEC Form SCHEDULE 13D filed by Aspen Neuroscience Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13d-filed-by-aspen-neuroscience-inc-6779681)
- 2026-11-06 22:34 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by Aspen Neuroscience Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-aspen-neuroscience-inc-6779621)
- 2026-11-06 14:45 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by Aspen Neuroscience Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-aspen-neuroscience-inc-6778300)
- 2026-11-04 23:47 UTC [Insider Buy] [Director Thompson Peter A. converted options into 2,589,132 shares and bought $15,000,000 worth of shares (1,000,000 units at $15.00) (SEC Form 4)](https://www.quantisnow.com/insight/director-thompson-peter-a-converted-options-into-2589132-shares-and-6773796)
- 2026-11-04 23:43 UTC [Insider Buy] [Director Orbimed Advisors Llc converted options into 2,589,132 shares and bought $15,000,000 worth of shares (1,000,000 units at $15.00) (SEC Form 4)](https://www.quantisnow.com/insight/director-orbimed-advisors-llc-converted-options-into-2589132-shares-and-6773795)
- 2026-11-03 14:17 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by Aspen Neuroscience Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-aspen-neuroscience-inc-6768914)
- 2026-11-03 02:50 UTC [Insider Buy] [Large owner Arch Venture Fund X, L.P. bought $19,999,995 worth of shares (1,333,333 units at $15.00) and converted options into 2,421,589 shares (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-arch-venture-fund-x-lp-bought-19999995-worth-6768073)
- 2026-11-03 02:46 UTC [Insider Buy] [Large owner Arch Venture Partners Xiv, L.P. bought $18,000,000 worth of shares (1,200,000 units at $15.00) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-arch-venture-partners-xiv-lp-bought-18000000-worth-6768072)
- 2026-11-03 02:05 UTC [SEC Form 4] [Director Spaventa Andrew converted options into 250,415 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-spaventa-andrew-converted-options-into-250415-shares-sec-form-6768067)
- 2026-11-03 02:03 UTC [SEC Form 4] [Executive Chair Hasnain Faheem converted options into 36,349 shares (SEC Form 4)](https://www.quantisnow.com/insight/executive-chair-hasnain-faheem-converted-options-into-36349-shares-sec-6768066)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ASPE
- Earnings history: https://www.quantisnow.com/earnings/ASPE
- Dividend history: https://www.quantisnow.com/dividends/ASPE
- Insider transactions: https://www.quantisnow.com/insiders/ASPE
- Options chain: https://www.quantisnow.com/options/ASPE
- SEC 8-K filings only: https://www.quantisnow.com/company/ASPE/8-k
- RSS and alerts for ASPE: https://www.quantisnow.com/docs/rss-feeds.md